A significant proportion of mucosal squamous cell carcinomas of the head and neck (HNSCC; particularly of the oropharynx) are directly attributable to the human papillomavirus (HPV). The increase in the incidence of HPV-related tumours has been postulated to be due to changing sexual practices in the community. We analysed 136 formalin-fixed paraffin-embedded squamous cell carcinomas from the oral cavity (n=40) and oropharynx (n=96) recruited from the Princess Alexandra Hospital (Brisbane, Australia). Samples were analysed for the presence of HPV DNA using a combination of mucosal HPV general primer GP+ PCR and sequencing; p 16INK4a expression was assessed by immunohistochemistry. Each patient completed a questionnaire detailing their lifestyle factors, such as tobacco smoking and alcohol consumption, marital status, and sexual behaviour and history. The HPV DNA prevalence was 5 % in the oral cavity cancers and 72 % in the oropharyngeal cancers (P<0.0001). HPV-16 was the most commonly detected HPV type (found in 91 % of all HPV-positive tumours). There was a strong correlation between HPV DNA positivity and positive p16 INK4a staining in oropharyngeal tumours (P<0.0001). Having an HPV-related tumour was associated with being married or having been married previously (P=0.046), an increasing number of passionate kissing partners (P=0.046), ever having given oral sex (P=0.0007) and an increasing number of oral sex partners (P=0.0015). This study found a higher prevalence of HPV in oropharyngeal compared to oral cavity tumours, with a strong association being identified between oral sex behaviours and HPV-positive tumours. Further research is needed to establish that vaccines will reduce the transmission and carriage of oropharyngeal HPV infections.
INTRODUCTION
Squamous cell carcinoma (SCC) of the head and neck cancer (HNSCC) is the sixth most common cause of cancer worldwide [1, 2] . In Australia, it affects approximately 4000 persons per year (3.4 % of all cancer diagnoses per year in Australia), with the number having increased over the past two decades [3, 4] . HNSCC includes SCC of mucosal anatomic sub-sites: the oral cavity (tongue, buccal mucosa), oropharynx (base of tongue, palatine tonsil), hypopharynx (posterior wall, post-cricoid region) and larynx (glottis, supraglottis, subglottis), and nasal cavity. Traditionally, tobacco smoking and alcohol consumption were the risk factors for cancers of the head and neck, having synergistic carcinogenic effects, and tumours related to these risk factors have demonstrated a decline in incidence of approximately 50 % [1, 2, [5] [6] [7] .
Human papillomavirus (HPV) infection is now an established risk factor for a subset of HNSCC, particularly in the oropharynx, where approximately 80 % of tumours are attributable to HPV [1, [7] [8] [9] [10] [11] . Over the past few decades there has been a clear and significant increase in the incidence of oropharyngeal tumours related to HPV, with an estimated increase of 225 % between 1984 and 2004 in America [7] . HPV-related tumours are a biologically distinct entity, occurring in younger, white, male patients, usually without a significant history of tobacco smoking or excessive alcohol intake [5, 9, 12, 13] . Overall, HPV-related tumours in the oropharynx have much more favourable prognosis and improved overall survival when compared with HPV-negative tumours [1, 9, 14] .
The distinct behavioural risk factor associated with HPVrelated HNSCC is, rather than tobacco smoking or excess alcohol consumption, past sexual behaviours. It is postulated that changing sexual practices in the community are contributing to the rising incidence of HPV-associated HNSCC [11, 15] . Across a number of studies, oral HPV infection in healthy participants has been correlated with sexual practices such as ever having had oral sex and an increasing number of oral sex partners, an increasing number of lifetime sexual partners, open mouth or passionate kissing and younger age at sexual debut [1, 5, 16] . Patients with HPVrelated tumours have also been found to have had higher numbers of oral sex partners and an increasing number of lifetime sexual partners, although a direct causative link has not been established [17, 18] .
We performed a case-case comparison study to compare risk factors such as past sexual behaviours between HPV DNA and p16
INK4a -positive and -negative squamous cell carcinomas in the oral cavity and oropharynx, with the secondary aim of establishing the prevalence of HPV DNA in an Australian cohort of these tumours.
RESULTS

Patient characteristics
A total of 136 patients (96 oropharyngeal tumours and 40 oral cavity tumours) were eligible and had sufficient tissue for inclusion in this study. The majority of patients in each group were male. The patient demographics and tumour characteristics are presented in Table 1 .
Frequency of HPV DNA and p16
INK4a expression, and associated clinical factors HPV DNA was detected in 71 of the 136 specimens (overall prevalence 52 %). In the oral cavity, HPV DNA was detected in 2 of the 40 included specimens (5 %), and in the oropharynx it was detected in 69 of the 96 included specimens (72 %; P<0.0001). HPV-16 was detected in all but six of the HPV DNA-positive specimens. One each of HPV-6, HPV-18, HPV-33, HPV-35, HPV-45 and HPV-59 were detected in the remaining specimens. All specimens were b-globinpositive.
The immunohistochemistry results for p16
INK4a staining, along with HPV DNA status, are presented in Table 2 . The p16
INK4a status was not available for four specimens due to insufficient tissue. In oropharyngeal tumours, the majority of tumours that were positive for HPV DNA also over-expressed p16 INK4a [60/64, P<0.0001; kappa 0.54 (CI 0.35, 0.73)]. In tumours of the oral cavity, the majority were negative for HPV DNA and also did not over-express p16 INK4a , although this did not reach statistical significance, and there were no tumours in the oral cavity containing HPV DNA and over-expressing p16 INK4a . No significant difference in age, smoking or alcohol status was observed with HPV DNA status or p16
INK4a status of the tumour in any subsite.
Sexual behaviours correlating with HPV status in tumours After evaluating tumours for the presence of HPV DNA and separately for p16
INK4a expression, we performed a casecase comparison to determine any differences in behaviours or characteristics between tumours with or without evidence of HPV infection. Significant differences were seen between HPV DNA-and p16
INK4a -positive and -negative tumour groups with respect to several of the lifestyle and sexual behaviour factors investigated (Table 3) . Having a HPV DNA-and p16 INK4a -positive tumour was associated with being married or having been married previously and with an increasing number of passionate kissing partners over the lifetime of the patient. The most significant finding, however, was that ever having had oral sex (P=0.0007) and having had an increasing lifetime number of oral sex partners were significantly associated with having a tumour that was positive for both HPV DNA and p16
INK4a (P=0.0015; 
DISCUSSION
The rise in HPV-related oropharyngeal tumours has been postulated to be associated with changing sexual practices in the general population. This study is the first conducted in Australia to investigate the relationship between sexual behaviours and the prevalence of HPV in tumours of the oropharynx and oral cavity. We have confirmed that the prevalence of HPV in tumours of the oral cavity in Australia remains low at approximately 5 %, as we have observed previously [19, 20] . However, we have found a prevalence of HPV in oropharyngeal tumours of approximately 72 % (2013-2015), which is much higher than the prevalence of 49 % that we observed previously (2004) (2005) (2006) (2007) (2008) (2009) (2010) in patients recruited from the same head and neck cancer clinic [19] . This is consistent with the increasing incidence of HPVassociated oropharyngeal SCC, both in Australia [21] and internationally [7] .
HPV-related disease is a clinical entity that is distinct from those tumours of the head and neck that are related to the traditional risk factors of tobacco smoking and alcohol consumption, and this has been recognized in the most recent head and neck cancer staging guidelines [22] . Our understanding of the pathophysiology and outcomes of this disease has improved significantly, while patient outcomes have improved [1, 6, 23] . At the same time, a low prevalence of high-risk or oncogenic HPV infections in the saliva of healthy study participants in the general population has been discovered [16, 24, 25] . However, there is still a lack of understanding concerning which of these people will go on to develop a HPV-related tumour, and how to identify them early.
We have demonstrated that Australian patients with HPV DNA-and p16 INK4a -positive tumours were significantly more likely to ever have had oral sex, and to have had an increasing number of oral sex partners over their lifetime, than patients with HPV DNA-and p16
INK4a -negative tumours. Participants with HPV-positive tumours were also more likely to have an increasing lifetime number of passionate kissing partners. All statistically significant differences were observed across analyses for HPV DNA and p16
INK4a separately, as well as in a combined analysis. This is consistent with previous studies, as all of the limited number of studies published to date investigating associations between sexual behaviours and HPV-related oropharyngeal tumours have demonstrated a strong association between oral sexual practices and having a HPV-related tumour [8, 17, 18, 26, 27] . Although our group has previously investigated the sexual behaviours of Australian patients with oropharyngeal versus head and neck cancers at other mucosal subsites [28] , this is the first study in Australia to report an association between past oral sexual behaviour and the presence of HPV-related tumours in the oropharynx.
In contrast to these previous studies, we did not demonstrate a significant difference for the factors ever having had sexual intercourse or lifetime number of sexual intercourse partners between participants with HPV-related and unrelated tumours. There were only small numbers of participants from either group answering 'No' to ever having sexual intercourse, and this is likely reflected in the lack of difference between the groups. Finally, we also identified that participants with HPV-related tumours were more likely to be married or to have been married than their HPV-negative counterparts, although this may reflect our patient cohort and deserves further clarification. We have previously evaluated sexual practices in head and neck cancer patients (including both SCC and other diagnoses), and our findings were consistent with those of the present study, demonstrating that patients with oropharyngeal tumours were more likely to have ever given oral sex compared to non-oropharyngeal tumour patients, and were more likely to have had greater numbers of lifetime sexual partners [kissing, oral sex (over four to five partners) and sexual intercourse] [28] . The participants in our current study were a subgroup of the larger cohort of participants included in our previous study. This study was restricted to a smaller patient cohort because of the limited availability of archival tumour material for analysis. We also did not observe any significant difference in sexual orientation between patients with HPV-related tumours, and those with HPV-negative tumours, although this needs to be interpreted with caution, as over 97 % of our patient cohort reported being heterosexual.
While HPV-16 was identified in the majority of oral cavity and oropharyngeal tumours containing HPV DNA, we did identify a small number of other HPV types. These included one each of HPV-18, HPV-33, HPV-35, HPV-45 and HPV-59, all high-risk or oncogenic HPV types. Of note, one tumour contained HPV-6, a low-risk HPV type. This tumour occurred in the oropharynx of a 41-year-old male patient with the classic risk factors of heavy tobacco use and excessive alcohol intake, who presented at a clinically advanced stage (T4a N3 M0) at diagnosis. This tumour did not over-express p16 INK4a , and it is possible that the HPV identified in this tumour was merely a bystander infection that did not contribute to carcinogenesis.
We used a sensitive, specific and reproducible method of HPV DNA detection and p16
INK4a status determination in this study. The questionnaire given to participants was confidential, which significantly increased the response rates for personal questions. While some participants chose not to answer some personal questions, our response rate overall for the sexual questionnaire was very high, approximately 90 %, giving an accurate reflection of the participant cohort and limiting the selection bias. We performed a case-case comparison study to lessen the influence of differential recall bias, as our results rely heavily on patient recall of past events. In addition, the results were analysed to compare the results for differences between both HPV DNAand p16
INK4a -positive and -negative groups, and then with these combined, as is done in clinical practice. One limitation of this study was the relatively small sample size, resulting in loss of power for some analyses, which means we may have failed to detect some true associations. Another limitation of this study is that we used a DNA technique to detect HPV, and not an RNA technique. Therefore, the percentage of truly HPV-positive cases may be slightly different from the reported figures.
We found that ever having given oral sex, an increasing lifetime number of oral sex partners and marital status correlated significantly with having a HPV-positive oropharyngeal tumour. There is increasing evidence to support the hypothesis that sexually transmitted oral oncogenic HPV infections may be contributing to the rise in HPV-related oropharyngeal tumours [11, 15, 17] . We do not yet fully understand the incidence and natural history of these infections and unanswered questions still remain regarding who will go on to develop an HPV-related cancer, and why. Further research needs to be conducted to fully establish the natural history of oral oncogenic HPV infections to further understand the factors that predispose people with higher numbers of sexual partners to the risk of developing an HPV-related HNSCC.
METHODS Participants
Eligible patients were aged 18 years and older, with a biopsyconfirmed primary SCC of the oropharynx or oral cavity, who presented consecutively to the Head and Neck clinic at the Princess Alexandra Hospital, Brisbane, Australia, between 2013 and 2015 and and gave their informed written consent to participate. One hundred and thirty-six patients had sufficient formalin-fixed paraffin-embedded (FFPE) tissue for HPV DNA analysis. Each patient completed a questionnaire detailing their medical history and lifestyle factors, such as tobacco smoking, alcohol consumption and marital status. In a separate, previously validated, questionnaire we asked about their sexual behaviour and history [24, 28, 29] . Participants were asked to select from predetermined categories the number of partners with whom they had engaged in passionate kissing (defined as 'open-mouthed kissing'), oral sex (giving only) and sexual intercourse (vaginal and anal) ('none', '1', '2-3', '4-7', '8-15', '16-28', '29 or more'). For oral sex and sexual intercourse, we also asked their age at first experience. Participants were also asked to report their sexual orientation ('men only'; 'mostly men, sometimes women'; 'equally men and women'; 'mostly women, sometimes men'; 'women only'). All questions in the second questionnaire had the option 'prefer not to answer'. Both questionnaires are included in the Supplementary Material (available in the online version of this article).
Clinical data were obtained from the patients' medical records, including date, subsite and stage of diagnosis; treatment; and recurrence. Histological data were extracted from the pathology reports accompanying each specimen. 
PCR analysis
One formalin-fixed paraffin-embedded specimen was available for each patient. DNA was extracted from one block for each patient, using the QIAamp DNA FFPE Tissue kit (Qiagen) as described by the manufacturer.
The samples of extracted DNA were analysed by PCR for the presence of HPV DNA using GP5+ and GP6+ primers [30] , and by b-globin PCR using PCO3 and PCO4 primers [31] to ensure that a sufficient quantity of human DNA was present in the sample, and that no PCR-inhibiting agents were present. The final volume of PCR solution (25 µl) contained 5 µl of extracted DNA sample, 0.5 µmol l À1 per primer, 0.2 mmol l À1 of each dNTP (Fisher), 1Â Gold buffer, 2.0 mmol l À1 MgCl 2 and 1 U of AmpliTaq Gold (Applied Biosystems).
A BioRad S1000 PCR machine was used. For the GP+ PCR, an initial step of denaturation at 94 C for 10 min was followed by 40 cycles of amplification: 94 C for 1.5 min, 40 C for 1.5 min and 72 C for 2 min. This was followed by a final elongation step of 4 min at 72 C. The b-globin PCR protocol consisted of an initial denaturation step of 10 min at 94 C, followed by 40 amplification cycles -94 C for 1.5 min, 50 C for 1.5 min and 72 C for 2 min -and then a final elongation step of 4 min at 72 C.
Reagent-grade water was used as a negative control for all reactions, and HeLa cells (HPV-18-positive cell line) were used as a positive control for both reactions. The resulting PCR products were examined on a 1.5 % agarose gel containing ethidium bromide using UV light. Patients were considered positive if the sample tested positive at least once by PCR.
HPV sequencing
All samples that were positive for HPV by PCR were sequenced to determine their HPV type. Ten microlitres of PCR reaction were purified with the Agencourt AMPure XP PCR purification kit on a magnetic 96-ring SPRIPlate. The sequencing reaction had a total volume of 15 µl, and contained 10.5 µl of purified PCR product, BigDye terminator and 1 µl 3.25 nM sequencing primer. After an initial step of 96 C for 2 min, 20 cycles followed, each consisting of 96 C for 10 s, 50 C for 5 s and 60 C for 2 min. This was performed in a BioRad S1000 PCR machine.
The sequence reactions were then purified with the Agencourt CleanSEQ dye-terminator removal kit in a magnetic 96-ring SPRIPlate. The purified sequencing reactions were analysed with an automated DNA sequencer (ABI model 3100). These sequences were compared with the available sequences in GenBank using the BLAST server (http://blast. ncbi.nlm.nih.gov).
Immunohistochemistry
Immunohistochemistry (IHC) was performed for p16 INK4a . FFPE tumour sections (4 µm) were affixed to Menzel Superfrost Plus adhesive slides and air-dried overnight at 37 C, before being dewaxed and rehydrated through descending graded ethanol to water using a Sakura DRS stainer. For all stains, antigen retrieval was performed in a Biocare Medical Decloaking chamber, followed by washing in TBS. Mouse anti-p16
INK4a IgG1 (#G175-405; BD Pharmingen) was used according to the protocol recommended by the supplier. Human breast carcinoma was used as positive control in each IHC batch. All slides were scored by an independent reviewer (S. B., a pathologist specialising in head and neck cancer pathology), who was blinded to the HPV status and clinical data.
Statistical analysis
We performed a case-case comparison study to compare patient characteristics and lifestyle factors (including past sexual behaviours) between HPV DNA-and p16
INK4a -positive and -negative tumours. For comparisons, we used the t-test for normally distributed continuous variables. For categorical variables, we used the chi-square test or Fischer's exact test for small samples when the expected number in any cell was <5. We used Cohen's kappa to measure agreement between HPV status and p16
INK4a expression in the same tumour. All analyses were conducted in SAS (version 9.4) and all significance tests were two-sided tests at a=0.05. 
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